Publications and communications of Céline GREGOIRE

El Moussaoui, M., Desmecht, S., Lambert, N., Maes, N., Braghini, J., MARECHAL, N., Quintana, C., BRIQUET, K., Gofflot, S., Toussaint, F., Hayette, M.-P., Vermeersch, P., Lutteri, L., GREGOIRE, C., Beguin, Y., Rahmouni, S., Moutschen, M., Desmecht, D., & Darcis, G. (2023). Cluster Analysis Identifies Distinct Patterns of T-Cell and Humoral Immune Responses Evolution Following a Third Dose of SARS-CoV-2 Vaccine in People Living with HIV. Viruses, 15, 1435. doi:10.3390/v15071435

El Moussaoui, M., Desmecht, S., Tashkeev, A., Lambert, N., Maes, N., Braghini, J., MARECHAL, N., Quintana, C., BRIQUET, K., Gofflot, S., TOUSSAINT, F., Hayette, M.-P., Vermeersch, P., Lutteri, L., Grégoire, C., Beguin, Y., Rahmouni, S., Moutschen, M., Desmecht, D., & Darcis, G. (05 September 2022). Reduced T-cell response following a third dose of SARS-CoV-2 vaccine in infection-naïve people living with HIV. Journal of Infection, 85, 751-755. doi:10.1016/j.jinf.2022.09.006

GREGOIRE, C.* , LAYIOS, N.* , LAMBERMONT, B., LECHANTEUR, C., BRIQUET, A., Bettonville, V., BAUDOUX, E., THYS, M., Dardenne, N., Misset, B.* , & BEGUIN, Y.*. (04 July 2022). Bone Marrow-Derived Mesenchymal Stromal Cell Therapy in Severe COVID-19: Preliminary Results of a Phase I/II Clinical Trial. Frontiers in Immunology, 13, 932360. doi:10.3389/fimmu.2022.932360
* These authors have contributed equally to this work.

El Moussaoui, M., Maes, N., Hong, S. L., Lambert, N., Gofflot, S., DELLOT, P., Belhadj, Y., Huynen, P., Hayette, M.-P., Meex, C., Bontems, S., Defêche, J., Godderis, L., Molenberghs, G., Meuris, C., Artesi, M., Durkin, K., Rahmouni, S., GREGOIRE, C., ... DARCIS, G. (14 June 2022). Evaluation of Screening Program and Phylogenetic Analysis of SARS-CoV-2 Infections among Hospital Healthcare Workers in Liège, Belgium. Viruses, 14 (6), 1302. doi:10.3390/v14061302

GREGOIRE, C.* , HUYNEN, P.* , Gofflot, S., Seidel, L., Maes, N., VRANKEN, L., DELCOUR, S., MOUTSCHEN, M., HAYETTE, M.-P., KOLH, P., MELIN, P., & BEGUIN, Y. (13 June 2022). Predictive factors for the presence and long-term persistence of SARS-CoV-2 antibodies in healthcare and university workers. Scientific Reports, 12, 9790. doi:10.1038/s41598-022-13450-4
* These authors have contributed equally to this work.

Kegyes, D.* , Constantinescu, C.* , Vrancken, L., Rasche, L., Grégoire, C., Tigu, B., Gulei, D., Dima, D., Tanase, A., Einsele, H., Ciurea, S., Tomuleasa, C., & Caers, J. (07 June 2022). Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient? Journal of Hematology and Oncology, 15 (1), 78. doi:10.1186/s13045-022-01296-2
* These authors have contributed equally to this work.

GREGOIRE, C., SERVAIS, S., WILLEMS, E., BAUDOUX, E., LECHANTEUR, C., BRIQUET, A., Bettonville, V., DETRY, O., ERPICUM, P., JOURET, F., LOUIS, E., BARON, F., & BEGUIN, Y. (April 2022). Immunothérapie cellulaire au CHU de Liège : avancées, défis et perspectives. Revue Médicale de Liège, 77 (4), 206-211.

HUYNEN, P.* , GREGOIRE, C.* , GOFFLOT, S., SEIDEL, L., MAES, N., VRANKEN, L., DELCOUR, S., MOUTSCHEN, M., HAYETTE, M.-P., KOLH, P., MELIN, P., & BEGUIN, Y. (25 March 2022). Long-term longitudinal evaluation of the prevalence of SARS-CoV-2 antibodies in healthcare and university workers. Scientific Reports, 12 (1), 5156. doi:10.1038/s41598-022-09215-8
* These authors have contributed equally to this work.

Massart, N., Maxime, V., Fillatre, P., Razazi, K., Ferré, A., Moine, P., Legay, F., Voiriot, G., Amara, M., Santi, F., Nseir, S., Marque-Juillet, S., Bounab, R., Barbarot, N., Bruneel, F., Luyt, C.-E., the COVID ICU Bacteremia Study Group on behalf of the COVID-ICU Investigators, KISOKA, G. (Other coll.), GREGOIRE, C. (Other coll.), & Lambermont, B. (Other coll.). (January 2022). Correction to: Characteristics and prognosis of bloodstream infection in patients with COVID-19 admitted in the ICU: an ancillary study of the COVID-ICU study (Annals of Intensive Care, (2021), 11, 1, (183), 10.1186/s13613-021-00971-w). Annals of Intensive Care, 12 (1). doi:10.1186/s13613-022-00979-w

COVID-ICU group, for the REVA network, COVID-ICU investigators, KISOKA, G., GREGOIRE, C., & LAMBERMONT, B. (08 December 2021). Benefits and risks of noninvasive oxygenation strategy in COVID-19: a multicenter, prospective cohort study (COVID-ICU) in 137 hospitals. Critical Care, 25 (1), 421. doi:10.1186/s13054-021-03784-2

LAMBERMONT, B., COVID-ICU Group on behalf of the REVA Network and the COVID-ICU Investigators, KISOKA, G., & Grégoire, C. (2021). Clinical characteristics and day-90 outcomes of 4244 ctritically ill adults with COVID-19: a prospective cohort study. Intensive Care Medicine. doi:10.1007/s00134-020-06294-x

Ritacco, C.* , Ehx, G.* , GREGOIRE, C., Daulne, C., WILLEMS, E., SERVAIS, S., BEGUIN, Y., & Baron, F. (2021). High proportion of terminally-differentiated regulatory T cells after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation, 56, 1828-1841. doi:10.1038/s41409-021-01221-0
* These authors have contributed equally to this work.

GREGOIRE, C. (2020). Mesenchymal stromal cell-based immunomodulation in graft-versus-host disease and Crohn's disease [Doctoral thesis, ULiège - Université de Liège]. ORBi-University of Liège. https://orbi.uliege.be/handle/2268/260628

Delens, L., Ehx, G., SOMJA, J., Vrancken, L., Belle, L., SEIDEL, L., Grégoire, C., Fransolet, G., Ritacco, C., Hannon, M., DUBOIS, S., Beguin, Y., Baron, F., & Servais, S. (2019). In Vitro Th17-Polarized Human CD4(+) T Cells Exacerbate Xenogeneic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 25, 204-215. doi:10.1016/j.bbmt.2018.10.007

ERPICUM, P., WEEKERS, L., DETRY, O., BONVOISIN, C., DELBOUILLE, M.-H., GREGOIRE, C., BAUDOUX, E., BRIQUET, A., LECHANTEUR, C., MAGGIPINTO, G., SOMJA, J., Pottel, H., Baron, F., Jouret, F., & BEGUIN, Y. (2019). Infusion of third-party mesenchymal stromal cells after kidney transplantation: a phase I-II, open-label, clinical study. Kidney International, 95, 693-707. doi:10.1016/j.kint.2018.08.046

Grégoire, C., Ritacco, C., Hannon, M., SEIDEL, L., Delens, L., Belle, L., DUBOIS, S., Veriter, S., LECHANTEUR, C., BRIQUET, A., Servais, S., Ehx, G., Beguin, Y., & Baron, F. (2019). Comparison of Mesenchymal Stromal Cells From Different Origins for the Treatment of Graft-vs.-Host-Disease in a Humanized Mouse Model. Frontiers in Immunology, 10, 619. doi:10.3389/fimmu.2019.00619

GREGOIRE, C., BRIQUET, A., PIRENNE, C., LECHANTEUR, C., LOUIS, E.* , & BEGUIN, Y.*. (November 2018). Allogeneic mesenchymal stromal cells for refractory luminal Crohn's disease: A phase I-II study. Digestive and Liver Disease, 50 (11), 1251-1255. doi:10.1016/j.dld.2018.08.015
* These authors have contributed equally to this work.

Vrancken, L., Muller, J., Lejeune, M., Grégoire, C., Delens, L., Jaspers, A., Servais, S., DE PRIJCK, B., Baron, F., Caers, J., & Beguin, Y. (2018). Nouveautes dans la prise en charge du myelome. Revue Médicale Suisse, 14 (615), 1438-1442.

Delens, L., SERVAIS, S., Ehx, G., Vrancken, L., Fransolet, G., GREGOIRE, C., Hannon, M., DUBOIS, S., Daulne, C., BEGUIN, F., & BARON, F. (24 May 2017). Th17 cells impact on xenogeneic graft-versus-host disease [Poster presentation]. 2017 Immunology day FNRS-Immunology Doctoral School, Gosselies, Belgium.

GREGOIRE, C., DETRY, O., Jouret, F., BRIQUET, A., LECHANTEUR, C., BAUDOUX, E., Beguin, Y., & GIET, O. (2017). The use of mesenchymal stromal cells in solid organ transplantation. In The Biology and Therapeutic Application of Mesenchymal Cells (pp. 825-835). Hoboken, United States: John Willey & Sons, Inc.

GREGOIRE, C., LECHANTEUR, C., BRIQUET, A., BAUDOUX, E., BARON, F., LOUIS, E., & BEGUIN, Y. (2017). Review article: mesenchymal stromal cell therapy for inflammatory bowel diseases. Alimentary Pharmacology and Therapeutics, 45, 205-221. doi:10.1111/apt.13864

GREGOIRE, C., Louis, E., BRIQUET, A., LECHANTEUR, C., BAUDOUX, E., GIET, O., Beguin, Y., & BARON, F. (2017). The role of mesenchymal stromal cells in the treatment of ulcerative colitis and Crohn’s disease. In The Biology and Therapeutic Application of Mesenchymal Cells (pp. 730-753). Hoboken, United States: John Wiley & Sons, Inc.

Delens, L., SERVAIS, S., Ehx, G., Vrancken, L., Fransolet, G., GREGOIRE, C., Hannon, M., DUBOIS, S., Daulne, C., BEGUIN, Y., & BARON, F. (18 November 2016). Impact des cellules Th17 sur la GVH xénogénique [Paper presentation]. 16ème édition du congrès de la SFGM-TC, Société Francophone de Greffe de Moelle et de Thérapie Cellulaire, Liège, Belgium.

Grégoire, C., GUIOT, J., Vertenoeil, G., WILLEMS, E., HAFRAOUI, K., CORHAY, J.-L., LOUIS, R., & BEGUIN, Y. (February 2016). Yellow nail syndrome after allogeneic haematopoietic stem cell transplantation in two patients with multiple myeloma. Acta Clinica Belgica, 71, 428-430. doi:10.1080/17843286.2015.1122872

Grégoire, C., Beguin, Y., Hannon, M., DUBOIS, S., BAUDOUX, E., BRIQUET, A., LECHANTEUR, C., Ehx, G., & Baron, F. (29 January 2016). Umbilical cord mesenchymal stromal cells are superior to bone marrow and adipose tissue-derived mesenchymal stromal cells for the treatment of xenogeneic graft-versus-host disease in mice [Poster presentation]. 31th General Meeting of the Belgian Hematological Society.

SERVAIS, S., GREGOIRE, C., BARON, F., WILLEMS, E., BRIQUET, A., BAUDOUX, E., DELLOYE, O., GIET, O., LECHANTEUR, C., & BEGUIN, Y. (2016). Multipotent mesenchymal stromal cell therapy for steroid-refractory acute graft-versus-host disease after allogeneic stem cell transplantation. Belgian Journal of Hematology, 7, 229-235.

Rowart, P., ERPICUM, P., Detry, O., WEEKERS, L., Grégoire, C., LECHANTEUR, C., BRIQUET, A., Beguin, Y., Krzesinski, J.-M., & Jouret, F. (2015). Mesenchymal Stromal Cell Therapy in Ischemia/Reperfusion Injury. Journal of Immunology Research, 602597. doi:10.1155/2015/602597

DETRY, O., JOURET, F., VANDERMEULEN, M., ERPICUM, P., Delens, L., GREGOIRE, C., BRIQUET, A., WEEKERS, L., BAUDOUX, E., LECHANTEUR, C., & BEGUIN, Y. (December 2014). Cellules stromales mésenchymateuses et transplantation d'organes. Revue Médicale de Liège, 69, 53-56.

GREGOIRE, C., Nellessen, E., Defraigne, J.-O., & RADERMECKER, M. (November 2014). La prothèse valvulaire idéale n’existe toujours pas. Quels facteurs entrent en compte pour orienter les choix d’une valve mécanique ou biologique ? Revue Médicale de Liège, 69 (11), 600-604.

BRIQUET, A., GREGOIRE, C., Comblain, F., Servais, L., Zeddou, M., LECHANTEUR, C., & Beguin, Y. (2014). Human bone marrow, umbilical cord or liver mesenchymal stromal cells fail to improve liver function in a model of CCl4-induced liver damage in NOD/SCID/IL-2Ry(null) mice. Cytotherapy, 16, 1511-1518. doi:10.1016/j.jcyt.2014.07.003

VANDERMEULEN, M., GREGOIRE, C., BRIQUET, A., LECHANTEUR, C., BEGUIN, Y., & DETRY, O. (2014). Rationale for the potential use of mesenchymal stromal cells in liver transplantation. World Journal of Gastroenterology, 20 (44), 16418-32. doi:10.3748/wjg.v20.i44.16418

BRIQUET, A., Grégoire, C., Beguin, Y., & Gothot, A. (April 2012). Inhibition of the Jagged-1/Notch pathway increases the hematopoiesis-supportive activity of mesenchymal stem cells [Paper presentation]. ESH-EHA Workshop Anti-Inflammatory & Immune Modulatory Properties of MSCs, Mandelieu, France.

BRIQUET, A., Grégoire, C., Beguin, Y., & Gothot, A. (January 2011). Inhibition of the Jagged-1/Notch pathway increases the hematopoiesis-supportive activity of mesenchymal stem cells [Poster presentation]. 26th General Meeting of the Belgian Hematological Society, Liège, Belgium.